# A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

> **NCT03671148** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 444 (actual)

## Conditions studied

- Psoriatic Arthritis (PsA)

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Risankizumab

## Key facts

- **NCT ID:** NCT03671148
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-07
- **Primary completion:** 2020-06-22
- **Final completion:** 2026-06
- **Target enrollment:** 444 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03671148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03671148, "A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03671148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*